Mediterr J Rheumatol 2017;28(2):94-8
Rheumatology: Necessary adjustments to the realities of the new era in Greece
Authors Information
Rheumatologist, ex-President of the “Greek Rheumatology Society and Professional Association of Rheumatologists”, Athens, Greece
  1. Brussels Declaration on Rheumatic and Musculoskeletal Diseases http://www.eular.org/myUploadData/files/Brussels%20Declaration%2020101020%20-%20final%20final.pdf
  2. Andrianakos A, Trontzas P, Christoyannis F, Dantis P, Voudouris C, Georgountzos A, et al. Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG Study. J Rheumatol 2003;30:1589-601.
  3. Picavet H S J, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004;63:723-9.
  4. Eustice C. What is the effect of rheumatoid arthritis on mortality? About.com Website. http://arthritis.about.com/od/mortality/f/mortalityra.htm. Updated January 18, 2005. Accessed January 20, 2011.
  5. Andrianakos A A, Miyakis S, Trontzas P, Kaziolas G, Christoyannis F, Karamitsos D, et al. The burden of the rheumatic diseases in the general adult population of Greece: the ESORDIG study. Rheumatology (Oxford) 2005;44:932-8.
  6. Clarke Α, Symmons D. The burden of rheumatic disease. Medicine 2006:34;333-5.
  7. Dunlop D D, Manheim L M, Yelin E H, Song J, Chang R W. The costs of arthritis. Arthritis Rheum 2003;49:101-13.
  8. Pugner K M, Scott D I, Holmes J W, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
  9. Centers for Disease Control and Prevention (CDC). National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States 2003. Morb Mortal Wkly Rep 2007;56:4-7.
  10. Rice D. The economic burden of musculoskeletal conditions. In: Praemer A, Furner S, Rice D, editors. Rosemont IL: American Academy of Orthopaedic Surgeons;1999.
  11. Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bulletin of the World Health Organization 2003:81(9).
  12. Let’s work together. EULAR/Pare, 2009.
  13. http://www.fitforworkeurope.eu/Website-Documents/Fit%20for%20Work%20pan-European%20report.pdf
  14. Kiely P D W, Brown A K, Edwards C J, O’Reilly D T, Ostor A J K, Quinn M, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009;48:765-72.
  15. Cantini F, Niccoli L, Nannini C. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 2016;45:519-32.
  16. Eng G P. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring. Dan Med J 2016;63:B5311.
  17. Flouri I, Markatseli T E, Voulgari P V, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014;43:447-57.
  18. Smolen J S, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 2008;10:208.
  19. Robinson W H, Mao R. Curr Opin Rheumatol 2016;28:168-75.
  20. Lenert A, Lenert P. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. Clin Rheumatol 2017;36:1-8.
  21. Galo J S, Mehat P, Rai S K, Avina-Zubieta A, De Vera M A. What are the effects of medication adherence interventions in rheumatic diseases: a systematic review. Ann Rheum Dis 2016;75:667-73.
  22. http://www.ere.gr/assets/files/drasis/Sxedio_Drasis.pdf
  23. Sivera F, Ramiro S, Cikes N, Cutolo M, Dougados M, Gossec L, et al. Working Group on Training in Rheumatology across Europe. Rheumatology training experience across Europe: analysis of core competences. Arthritis Res Ther 2016;18:213.